← Back to Clinical Trials
Recruiting NCT06040073

Natural History of Coronary Atherosclerosis

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Coronary Artery Disease Progression
Sponsor China National Center for Cardiovascular Diseases
Study Type OBSERVATIONAL
Phase N/A
Enrollment 125
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-07-07
Completion 2025-06-30

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The present study sought to explore the predictive value of radial wall strain (RWS, derived solely from angiograms) for coronary artery lesion progression compared with lesion vulnerability assessed by optical coherence tomography (OCT). The lesion progression at 1 year was defined as an increase of ≥20% in diameter stenosis based on quantitative coronary angiography (QCA) evaluation.

Eligibility Criteria

Inclusion Criteria: * General Inclusion Criteria: 1. Age ≥18 years 2. Acute myocardial infarction ≤ 45 days 3. Planned coronary angiography examination or potential interventional treatment * Angiographic Inclusion Criteria: 1. The presence of at least 1 non-flow-restricting lesion (visually estimated diameter stenosis: 30%-80%; QFR \> 0.80) in any non-infarct related artery with RVD ≥2.5 mm by visual assessment Exclusion Criteria: * General exclusion Criteria: 1. Cardiogenic shock 2. Pregnant or woman of child-bearing potential 3. Life expectancy less than 1 year for non-cardiac causes 4. Unable to tolerate contrast agents or anticoagulant/antiplatelet therapy 5. Prior CABG or planned CABG * Angiographic exclusion Criteria: 1. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification, branch ostium cannot be shown clearly, severe overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to QF

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}